Navigation Links
deCODE genetics Announces Webcast of Conference Call to Discuss Third Quarter 2008 Financial Results
Date:10/28/2008

REYKJAVIK, Iceland, October 28 /PRNewswire-FirstCall/ -- deCODE genetics, Inc. (Nasdaq:DCGN) today announced that it will report its third quarter 2008 financial results in a press release to be issued on Thursday, November 6, after the close of the market in New York. The company will host a live webcast of its conference call to discuss these results and recent operating highlights on Friday, November 7, at 8am EST/1pm GMT.

The webcast can be accessed through the Investors page of deCODE's website, http://www.decode.com, or through http://www.earnings.com. Please log in to the webcast 15 minutes prior to the scheduled start of the call. The call will be archived for at least a week on each site. For those unable to listen to the webcast because of company firewall or other issues, a digitized audio replay will also be available by telephone from approximately 11:30am ET on Friday, November 7 and for one week thereafter. The dial-in replay numbers are: 1-(800)-475-6701 in the U.S., and +1-320-365-3844 for those calling from outside the U.S. The access code is 967723.

Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results, and the timing of events, to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to our ability to obtain financing and to form collaborative relationships, the effect of a potential delisting of our common stock from The Nasdaq Global Market, uncertainty regarding potential future deterioration in the market for auction rate securities which could negatively affect our cash position and result in additional permanent impairment charges, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10-K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. deCODE undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.

Contacts:

deCODE genetics,

Gisli Arnason,

+354-570-1825,

gisli.arnason@decode.is .


'/>"/>
SOURCE deCODE genetics Inc
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. deCODE Discovery Sheds Light on Risk of the Most Common Form of Skin Cancer
2. deCODE Receives Nasdaq Deficiency Notice Relating to Market Value
3. Researchers decode viral process that prepares cells for HIV infection
4. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Healthcare Conference 2008
5. deCODE genetics Announces Second Quarter 2008 Financial Results
6. deCODE genetics Announces Webcast of Conference Call to Discuss Second Quarter 2008 Financial Results
7. deCODE genetics to Webcast Presentations at Annual R&D Event
8. deCODE genetics to Webcast Presentation at Piper Jaffray Europe Conference
9. deCODE genetics Announces First Quarter 2008 Financial Results
10. deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor-Positive Breast Cancer
11. deCODE Lauds Federal Legislation to Ban Discrimination on the Basis of Genetic Information
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... England , December 8, 2016 ... das Unternehmen für Molekulargenetik, erweitert seine Palette an ... myPanel™ NGS Custom FH Panels, das ein schnelles ... (FH) ermöglicht. Das Panel bietet eine Erkennung von ... Variations (CNV) mit einem einzigen kleinen Panel und ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... the World Technology Awards. uBiome is one of just six company finalists in ... , In addition to uBiome, companies nominated as finalists in this year’s awards ...
(Date:12/8/2016)... 8, 2016 Savannah River Remediation LLC ... selected NewTechBio,s NT-MAX Lake & Pond Sludge ... bacteria, in conjunction with Hexa Armor/ Rhombo cover ... National Pollutant Discharge Elimination System requirements. ... steady history of elevated pH levels, above 8.5, ...
(Date:12/7/2016)... ... December 07, 2016 , ... A new study published ... of previously treated, advanced pancreatic cancer, liquid biopsies are not yet an adequate ... timing of blood sampling may improve the value of a blood-based test.” The ...
Breaking Biology Technology:
(Date:12/7/2016)... 2016   Veridium , a leader in ... new CEO James Stickland . Stickland, a ... experience, has served in senior executive roles for ... in expanding a pipeline of venture capital and ... recently served as managing director of U.K.-based fintech ...
(Date:12/6/2016)... -- Valencell , the leading innovator in performance ... third consecutive year of triple digit growth for its ... a 360 percent increase in companies who have acquired ... by sales of its wrist and ear Benchmark™ sensor ... for hearables for fitness and healthcare applications. ...
(Date:12/5/2016)... Dec. 5, 2016  The Office of Justice ... "Can CT Scans Enhance or Replace Medico Legal ... of supporting or replacing forensic autopsies with postmortem ... In response to recommendations made by ... using CT scans as a potential component of ...
Breaking Biology News(10 mins):